Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy
Circulation: Cardiovascular Imaging · 2026-08 · 19 (8)
DOI: 10.1161/circimaging.126.019832 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Circulation: Cardiovascular Imaging, 2026-08. Verfasst von Gregorio Tersalvi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine (G.T., M.C.B., H.J., M.G.R.-P., J.W.A., J.P.B., K.A.Y., N.S.A., I.C.C., M.G., J.J.M., M.M.R., P. Chareonthaitaw…. Hauptthemen laut MEDLINE: Cardiomyopathies, Single Photon Emission Computed Tomography Computed Tomography, Amyloid Neuropathies, Familial, Myocardium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Technetium-based cardiac amyloid radionuclide imaging enables noninvasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), but conventional planar and visual semiquantitative approaches have important limitations. We developed the quantitative 3-dimensional Mayo 3D Score, defined as the ratio of mean left ventricular myocardial radiotracer uptake to right atrial blood-pool uptake using computed tomography (CT)-fused single-photon emission CT (SPECT) volumes of interest, and sought to validate its diagnostic performance against myocardial pathology. METHODS: Consecutive patients who underwent 99m Tc-pyrophosphate SPECT/CT at Mayo Clinic for suspected ATTR-CM between June 2017 and January 2025 with archived myocardial tissue were included. Baseline characteristics, including demographics, echocardiogram, biomarkers, visual semiquantitative, and Mayo 3D Score metrics, were collected. Myocardial specimens underwent histopathologic confirmation of amyloid, with amyloid subtype determination and further semiquantitative grading of amyloid burden and deposition patterns. RESULTS: Among 230 patients (median age, 72 years; 78% male), 107 (47%) had ATTR-CM, of whom 9 had hereditary ATTR-CM. The Mayo 3D Score showed excellent discrimination against pathology (area under the receiver operating characteristic curve, 0.92 [0.88–0.96]), exceeding planar Perugini (0.87 [0.83–0.92]; P =0.006), and heart-to-contralateral lung ratio (0.86 [0.81–0.91]; P =0.004) and comparable to SPECT Perugini (0.90 [0.86–0.94]; P =0.12). A cutoff ≥1.0 yielded 86.0% sensitivity, 92.7% specificity, 91.1% positive predictive value, and 88.4% negative predictive value. Among ATTR-positive cases, the Mayo 3D Score correlated strongly with semiquantitative amyloid burden (Spearman ρ=0.69), was higher in pericellular than nodular deposition patterns ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine (G.T., M.C.B., H.J., M.G.R.-P., J.W.A., J.P.B., K.A.Y., N.S.A., I.C.C., M.G., J.J.M., M.M.R., P. Chareonthaitawee, O.F.A.E.), Mayo Clinic, Rochester, MN.
- Department of Laboratory Medicine & Pathology (M.C.B., J.J.M.), Mayo Clinic, Rochester, MN.
- Department of Quantitative Health Sciences (C.G.S.), Mayo Clinic, Rochester, MN.
- Department of Internal Medicine (P. Carey), Mayo Clinic, Rochester, MN.
- Mayo Clinic Alix School of Medicine, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN (A.G.).
- AGH McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA (D.R.D.).
ORCID-Profile: Gregorio Tersalvi, Christopher G Scott, Patricia Carey, Armin Garmany, Daniel R Davies, Jun Zhang, Carrie B Hruska, J Wells Askew, Kathleen A Young, Martha Grogan, Angela Dispenzieri, Joseph J Maleszewski, Margaret M Redfield, Panithaya Chareonthaitawee, Geoffrey B Johnson, Omar F AbouEzzeddine
Förderung
- NIGMS NIH HHS
Zitieren
APA
Tersalvi, G., Bois, M. C., Scott, C. G., Carey, P., Garmany, A., Davies, D. R., Hoffman, A. C., Zhang, J., Hruska, C. B., Jouni, H., Rodriguez-Porcel, M. G., Askew, J. W., Bois, J. P., Young, K. A., Anavekar, N. S., Chang, I. C., Grogan, M., Dispenzieri, A., Maleszewski, J. J., …, & AbouEzzeddine, O. F. (2026). Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy. Circulation: Cardiovascular Imaging, 19(8). https://doi.org/10.1161/circimaging.126.019832
Vancouver
Tersalvi G, Bois MC, Scott CG, Carey P, Garmany A, Davies DR, et al. Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy. Circulation: Cardiovascular Imaging. 2026;19(8). doi:10.1161/circimaging.126.019832
BibTeX
@article{Tersalvi2026,
author = {Tersalvi, Gregorio and Bois, Melanie C and Scott, Christopher G and Carey, Patricia and Garmany, Armin and Davies, Daniel R and Hoffman, Andrew C and Zhang, Jun and Hruska, Carrie B and Jouni, Hayan and Rodriguez-Porcel, Martin G and Askew, J Wells and Bois, John P and Young, Kathleen A and Anavekar, Nandan S and Chang, Ian C and Grogan, Martha and Dispenzieri, Angela and Maleszewski, Joseph J and Homb, Andrew C and Redfield, Margaret M and Chareonthaitawee, Panithaya and Johnson, Geoffrey B and AbouEzzeddine, Omar F},
title = {Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy},
journal = {Circulation: Cardiovascular Imaging},
year = {2026},
volume = {19},
number = {8},
doi = {10.1161/circimaging.126.019832}
}
EUVIMED